TNX-355 With Optimized Background Therapy (OBT) in Treatment-Experienced Subjects With HIV-1

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2004
This is a 48-week study to compare TNX-355 plus OBT to placebo plus OBT in HIV subjects. You must have a stable viral load of at least 10,000 copies/ml, been treated with highly active antiretroviral therapy (HAART) for at least 6 months, be triple class experienced, and presently failing or have failed a HAART regimen. Subjects will receive infusions every week for 8 weeks, then every two weeks.
Epistemonikos ID: 8882024bc06b91bae43abf52095506fa42e69276
First added on: Nov 24, 2021